Dare Bioscience, Inc. (DARE) Stock Price & Analysis

Dare Bioscience, Inc. (DARE) rose 3.78% to USD 1.92 as of June 10, 2026 at 02:29 UTC, according to Nexqual real-time market data.

DARE last closed at USD 1.85; the session ranged USD 1.85–1.97 on volume of 114,528 shares. Market capitalization is $28.76M, with a 52-week range of USD 1.27–9.19 (NCM). Source: Nexqual, June 10, 2026 at 02:29 UTC.

Key Statistics (as of June 10, 2026 at 02:29 UTC)

Technical Analysis (DARE)

Nexqual's technical model rates DARE "SELL" based on 1 bullish and 5 bearish signals across 124 daily candles, as of June 10, 2026 at 02:29 UTC.

Analyst Ratings (DARE)

Wall Street analysts rate DARE "None" based on 3 analysts, with a mean price target of USD 9.67 (range USD 8–12), per Nexqual as of June 10, 2026 at 02:29 UTC.

Earnings (DARE)

Recent Earnings History

Source: Nexqual, June 10, 2026 at 02:29 UTC.

Financials & Fundamentals (DARE)

Source: Nexqual, June 10, 2026 at 02:29 UTC.

Financial Health Score (DARE)

Nexqual rates Dare Bioscience, Inc.'s overall financial health "Weak" across five dimensions, as of June 10, 2026 at 02:29 UTC.

Ownership (DARE)

Source: Nexqual, June 10, 2026 at 02:29 UTC.

Leadership (DARE)

Dare Bioscience, Inc. is led by Sabrina Martucci Johnson (age 58), CEO, President, Principal Financial Officer, Secretary & Director, per Nexqual as of June 10, 2026 at 02:29 UTC.

Major Backers & Investors (DARE)

Notable institutional backers of Dare Bioscience, Inc. include Fidelity, US BANCORP \DE\, UBS Group AG, according to Nexqual as of June 10, 2026 at 02:29 UTC.

Active Investors

Index Funds (Passive)

Source: Nexqual, June 10, 2026 at 02:29 UTC.

From Dare Bioscience, Inc.'s Latest SEC 10-K Filing (filed 2026-03-26)

Key Strengths & Strategy (as disclosed to the SEC)

• In assessing which of our proprietary formulations are candidates for Section 503B compounding, in addition to the drug substance(s) being on the FDA's interim 503B Category 1 list of bulk drug substances, we take into account whether we believe the formulation is ready for cGMP manufacturing at scale to meet potential market demand and that the data from nonclinical and clinical studies of the formulation to date will be compelling to healthcare providers.
• For select proprietary formulations, we are pursuing both traditional FDA approval and earlier market access via outsourcing facilities registered under Section 503B of the Federal Food, Drug, and Cosmetic Act (FDCA), which may compound and distribute certain drugs without patient-specific prescriptions.
• We do not believe bringing our select proprietary formulations to market via Section 503B compounding will negatively impact the regulatory process or commercial opportunity for an FDA-approved product utilizing the same proprietary formulation.
• As a compounded drug, DARE to PLAY is not covered by insurance and is not eligible for reimbursement through government or commercial health plans, including Medicare and Medicaid, or under insurance formularies applicable to FDA-approved prescription drug products.

Partnerships

• In 2022, we entered into an agreement with an affiliate of Organon & Co., Organon International GmbH, or Organon, whereby Organon licensed exclusive worldwide rights to develop, manufacture and commercialize XACIATO.
• We previously were also collaborating on Ovaprene with Bayer Healthcare LLC, or Bayer, under a license agreement entered into in January 2020.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 02:29 UTC. This page is informational and not investment advice.